Standard BioTools Inc. Cash and Cash Equivalents, Fair Value Disclosure
Standard BioTools Inc. (LAB) had Cash and Cash Equivalents, Fair Value Disclosure of $14.05 million as of 2019-09-30, per its 10-Q filed 2019-11-08.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Financial Instruments, Financial Assets, Balance Sheet Groupings
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2019-11-08
- 2019-09-30: Cash and Cash Equivalents, Fair Value Disclosure $14.05M.
- 2019-06-30: Cash and Cash Equivalents, Fair Value Disclosure $15.93M.
- 2019-03-31: Cash and Cash Equivalents, Fair Value Disclosure $65.64M.
- 2018-12-31: Cash and Cash Equivalents, Fair Value Disclosure $17.68M; Cash and Cash Equivalents, Fair Value Disclosure as first filed $95.40M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure | Cash and Cash Equivalents, Fair Value Disclosure as first filed |
|---|---|---|
| 2019-09-30 | $14.05M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $15.93M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $65.64M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $17.68M 10-Q · filed 2019-11-08 | $95.40M 10-K · filed 2019-03-18 |
| 2018-09-30 | $35.83M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $39.42M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $41.97M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $58.06M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $60.94M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $39.60M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $44.10M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $35.05M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $32.31M 10-Q · filed 2016-11-09 | |
| 2015-12-31 | $29.12M 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |